XBiotech Inc.

NASDAQ:XBIT

Biotechnology

Healthcare
$1.73 -0.84%

-$0.02 today

Market cap
$52.74M
Beta
0.84
P/E (TTM)
-1.8
EPS (TTM)
-$1.32
52W Low $2.09High $3.61

Volume 0.06M

Average 0.03M

XBIT Operating Cash Flow

Cash generated by the company's core business operations during the period.

XBiotech Inc.NASDAQ: XBIT

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q1 FY2026 operating cash flow of $8.97M (cash outflow) rose 33.5% year over year, behind the +38.3% change in trailing-twelve-month operating cash flow. Sequentially, it fell 60.9% from the prior quarter. Over 3 fiscal years it compounded at +39.1% a year.

Context

  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +33.5% toward the trailing-twelve-month pace of +38.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.97M-60.9% QoQ
Last fiscal yearDec 2025
-$39.92M+28.9% YoY
LTMMar 2026
-$42.17M+38.3% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.5%——
1 year+28.9%——
3-year CAGR+39.1%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(39.92M) USD
Year-over-year change
-28.9%

Operating Cash Flow vs competitors

How XBIT compares with its peers on the latest reported figures

  • XBIT's LTM Mar 2026 operating cash flow of $42.17M is the 6th largest of the 9 companies compared; the peer median is $35.59M.
  • Its year-over-year change of +38.3% is the 2nd highest of 8, against a peer median of -3.8%.
  • Over three fiscal years its annual growth of +39.1% compares with a peer median of +13.9%.
XBIT Competitors Peer median
Operating Cash Flow for XBIT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$157.64M +312.0%-28.4%238.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$122.01M +2.4%+26.7%1335.5%
ACETAdicet Bio, Inc.LTM Mar 2026$91.34M -3.8%+28.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$64.67M -5.1%+28.3%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$42.79M -24.7%-23.9%—
XBITXBiotech Inc.LTM Mar 2026$42.17M +38.3%+39.1%—
ADAGAdagene Inc.LTM Jun 2024$28.4M —-31.5%3481.6%
GANXGain Therapeutics, Inc.LTM Mar 2026$19.37M +1.4%+7.9%—
NTRBNutriband Inc.LTM Apr 2026$4.36M -15.0%+19.8%241.9%
Peer median (excluding XBIT) $35.59M-3.8%+13.9%788.7%

Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.41M)(32.9M)(24.56M)(38.53M)(45.54M)
Depreciation & Amortization2.65M2.61M1.74M1.75M1.69M
Deferred Income Tax00005K
Stock-Based Compensation4.46M5.06M3.26M1.75M3.62M
Change in Working Capital79.75M7.6M2.72M(1.46M)3.64M
Accounts Receivables1.73M7.34M829K77K574K
Inventory00000
Accounts Payables(514K)357K91K(364K)(688K)
Other Working Capital78.53M(97K)1.8M(1.17M)3.75M
Other Non-Cash Items4.46M2.8M(1.89M)5.53M(3.33M)
Operating Cash Flow69.45M(14.82M)(18.73M)(30.96M)(39.92M)
Capital Expenditures(3.53M)(585K)(362K)(1.3M)(289K)
Acquisitions (Net)00000
Purchases of Investments0(63.31M)000
Sales of Investments00000
Other Investing Activities0061.86M00
Investing Cash Flow(3.53M)(63.89M)61.5M(1.3M)(289K)
Debt Repayment00010.25M(10.25M)
Common Stock Issued005K00
Common Stock Repurchased00000
Dividends Paid(75M)0000
Other Financing Activities8M0(14K)200K0
Financing Cash Flow(67.01M)0(9K)10.45M(10.25M)
Effect of Forex Changes705K(961K)(46K)(5.53M)3.33M
Net Change in Cash(383K)(79.68M)42.72M(27.35M)(47.13M)
Free Cash Flow65.92M(15.41M)(19.09M)(32.27M)(40.21M)

XBiotech Inc.

NASDAQ:XBIT

Intrinsic Alpha fair value

Locked

Current Price

$1.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.